Common Contracts
3 similar Assignment of Stock Agreement contracts by Estrella Immunopharma, Inc.
ASSIGNMENT OF STOCK AGREEMENTAssignment of Stock Agreement • October 5th, 2023 • Estrella Immunopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This ASSIGNMENT OF STOCK AGREEMENT (this “Agreement”), effective as of the Closing Date (as defined in that certain Agreement and Plan of Merger, dated as of September 30, 2022, by and among Estrella Biopharma, Inc., a Delaware corporation (the “Company”), TradeUP Acquisition Corp., a Delaware corporation (the “SPAC”), and TradeUp Merger Sub Inc., a Delaware corporation and a direct wholly-owned subsidiary of the SPAC (“Merger Sub”) (as may be amended, supplemented, restated or otherwise modified from time to time, the “Merger Agreement”)), pursuant to which, among other things, Merger Sub will merge with and into the Company, with the Company surviving such merger as a direct wholly-owned subsidiary of the SPAC (the “Merger”), is by and among Cheng Liu, Jiandong (Peter) Xu and Qian (Vicky) Yang (each, a “Transferor”), Smart Crest International Limited, a Hong Kong company (the “Transferee”) and the Company. Capitalized terms used but not defined herein shall have the meanings ascribed
ASSIGNMENT OF STOCK AGREEMENTAssignment of Stock Agreement • October 5th, 2023 • Estrella Immunopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This ASSIGNMENT OF STOCK AGREEMENT (this “Agreement”), effective as of the Closing Date (as defined in that certain Agreement and Plan of Merger, dated as of September 30, 2022, by and among Estrella Biopharma, Inc., a Delaware corporation (the “Company”), TradeUP Acquisition Corp., a Delaware corporation (the “SPAC”), and TradeUp Merger Sub Inc., a Delaware corporation and a direct wholly-owned subsidiary of the SPAC (“Merger Sub”) (as may be amended, supplemented, restated or otherwise modified from time to time, the “Merger Agreement”)), pursuant to which, among other things, Merger Sub will merge with and into the Company, with the Company surviving such merger as a direct wholly-owned subsidiary of the SPAC (the “Merger”), is by and among Cheng Liu, Jiandong (Peter) Xu and Qian (Vicky) Yang (each, a “Transferor”), Yanbing Xiao (the “Transferee”) and the Company. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Merger Agreement, a copy o
ASSIGNMENT OF STOCK AGREEMENTAssignment of Stock Agreement • October 5th, 2023 • Estrella Immunopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This ASSIGNMENT OF STOCK AGREEMENT (this “Agreement”), effective as of the Closing Date (as defined in that certain Agreement and Plan of Merger, dated as of September 30, 2022, by and among Estrella Biopharma, Inc., a Delaware corporation (the “Company”), TradeUP Acquisition Corp., a Delaware corporation (the “SPAC”), and TradeUp Merger Sub Inc., a Delaware corporation and a direct wholly-owned subsidiary of the SPAC (“Merger Sub”) (as may be amended, supplemented, restated or otherwise modified from time to time, the “Merger Agreement”)), pursuant to which, among other things, Merger Sub will merge with and into the Company, with the Company surviving such merger as a direct wholly-owned subsidiary of the SPAC (the “Merger”), is by and among Cheng Liu, Jiandong (Peter) Xu and Qian (Vicky) Yang (each, a “Transferor”), Yuandong Wang (the “Transferee”) and the Company. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Merger Agreement, a copy
